Among them, only the anti-angiogenesis agent bevacizumab, a humanized monoclonal antibody targeting vascular endothelial growth factor (VEGF), showed a promising capacity to prolong progression-free survival (PFS) in recurrent/progressive GBM patients, based on which it was approved for the treatment of relapsed GBM by Food and Drug Administration in 2009 (Vredenburgh et al., 2007; Friedman et al., 2009). This evidence concerns the gene VEGFA and glioblastoma.